脂质体布比卡因腹横肌平面阻滞用于剖宫产术后镇痛:多中心随机双盲对照试验
该多中心随机双盲试验纳入186例脊麻下择期剖宫产的足月产妇,比较腹横肌平面(TAP)阻滞使用脂质体布比卡因(LB)266 mg联合布比卡因HCl 50 mg与单用布比卡因HCl 50 mg的镇痛效果。但全治疗人群分析未见组间差异。
要点
- 在符合方案分析集中,LB联合布比卡因HCl的TAP阻滞较单用布比卡因HCl减少剖宫产术后72小时阿片消耗量。
- 全治疗人群分析中两组术后阿片消耗量无差异。
- LB联合组与单用组术后不良事件发生率分别为63.6%和56.2%,严重不良事件均罕见(约3%)。
核心结论
- 在纳入鞘内吗啡的多模式镇痛方案下,TAP阻滞使用LB联合布比卡因HCl可减少符合方案分析集剖宫产术后阿片消耗量。
- 全治疗人群分析未显示两组术后阿片消耗量存在差异。
研究设计与样本
- 多中心、随机、双盲、对照试验,纳入186例脊麻下择期剖宫产的足月妊娠产妇,按1:1随机分组。
- 干预组为TAP阻滞使用LB 266 mg联合布比卡因HCl 50 mg,对照组为布比卡因HCl 50 mg单用。
- 主要终点为术后72小时总阿片消耗量(口服吗啡当量,MED),在预先定义的符合方案分析集中评估。
主要发现
- 全治疗患者分析中两组术后阿片消耗量无差异。
- LB联合组63.6%患者发生治疗后不良事件,单用组为56.2%;治疗后严重不良事件两组均罕见(约3%)。
关键数值与推荐
- LB剂量266 mg,布比卡因HCl剂量50 mg。
临床怎么用
- 在包含鞘内吗啡的多模式镇痛方案中,剖宫产术后可考虑TAP阻滞使用LB联合布比卡因HCl以减少阿片消耗,但需注意该获益仅在符合方案分析集中观察到。
- 实施TAP阻滞时应确保正确 placement 并坚持多模式术后镇痛方案。
局限性
- 全治疗人群分析中两组术后阿片消耗量无差异,提示结果可能受方案依从性影响。
- 不良事件发生率在LB联合组略高(63.6% vs 56.2%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In women undergoing cesarean delivery under spinal anesthesia with intrathecal morphine, transversus abdominis plane (TAP) block with bupivacaine hydrochloride (HCl) may not improve postsurgical analgesia. This lack of benefit could be related to the short duration of action of bupivacaine HCl. A retrospective study reported that TAP block with long-acting liposomal bupivacaine (LB) reduced opioid consumption and improved analgesia following cesarean delivery. Therefore, we performed a prospective multicenter, randomized, double-blind trial examining efficacy and safety of TAP block with LB plus bupivacaine HCl versus bupivacaine HCl alone. METHODS: Women (n = 186) with term pregnancies undergoing elective cesarean delivery under spinal anesthesia were randomized (1:1) to TAP block with LB 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone. Efficacy was evaluated in a protocol-compliant analysis (PCA) set that was defined a priori. The primary end point was total postsurgical opioid consumption (oral morphine equivalent dosing [MED]) through 72 hours. Pain intensity was measured using a visual analog scale. Adverse events (AEs) after treatment were recorded through day 14. RESULTS: Total opioid consumption through 72 hours was reduced with LB plus bupivacaine HCl versus bupivacaine HCl alone (least squares mean [LSM] [standard error (SE)] MED, 15.5 mg [6.67 mg] vs 32.0 mg [6.25 mg]). This corresponded to an LSM treatment difference of -16.5 mg (95% confidence interval [CI], -30.8 to -2.2 mg; P = .012). The area under the curve of imputed pain intensity scores through 72 hours supported noninferiority of LB plus bupivacaine HCl versus bupivacaine HCl alone (LSM [SE], 147.9 [21.13] vs 178.5 [19.78]; LSM treatment difference, -30.6; 95% CI, -75.9 to 14.7), with a prespecified noninferiority margin of 36 (P = .002). In an analysis of all treated patients, including those not meeting criteria for inclusion in the PCA, there was no difference in postsurgical opioid consumption between groups. In the LB plus bupivacaine HCl group, 63.6% of patients experienced an AE after treatment versus 56.2% in the bupivacaine HCl-alone group. Serious AEs after treatment were rare (≈3% in both groups). CONCLUSIONS: TAP block using LB plus bupivacaine HCl as part of a multimodal analgesia protocol incorporating intrathecal morphine resulted in reduced opioid consumption after cesarean delivery in the PCA set. Results suggest that with correct TAP block placement and adherence to a multimodal postsurgical analgesic regimen, there is an opioid-reducing benefit of adding LB to bupivacaine TAP blocks after cesarean delivery (ClinicalTrials.gov identifier: NCT03176459).
引用
- Nedeljkovic SS, Kett A, Vallejo MC, et al. Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Delivery in a Multicenter, Randomized, Double-Blind, Controlled Trial. Anesth Analg. 2020. PMID: 32739962. doi:10.1213/ANE.0000000000005075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。